ATI-1013 (0.2 g)
Phase 1Biologic
ATI-1013 (0.2 g) is one of 8 biologic programs targeting Single Ascending Dose. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
7
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
16 competitors in Single Ascending Dose
#DrugCompanyPhaseTrials
1WVE-006
WWave Life Sciences Ltd.
Phase 2
SYH2085
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Phase 1
JMT202
SShanghai JMT-Bio Inc.
Phase 1
HRS-4029
BBeijing Suncadia Pharmaceuticals Co., Ltd
Phase 1
Gensci142
Changchun GeneScience Pharmaceutical Co., Ltd.Phase 1
DT-216P2
DDesign Therapeutics, Inc.
Phase 1
ATI-1013 (0.2 g)
AAntidote Therapeutics, Inc
Phase 1
NM-101
NNeuramedy Co. Ltd.
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ATI-1013 (0.2 g). EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 1[1]
- Company
- AAntidote Therapeutics, Inc